Payment overview · 2025
General Payments
$706.42
31 reported records · 7 companies
Healthcare provider profile · identity verified
Benjamin Thomas Carter, MD
Allopathic & Osteopathic Physicians|Family Medicine · KOSCIUSKO, MS · NPI 1902868961
Verified facts
What the public records show
CMS Open Payments records show Benjamin Thomas Carter, MD received $706.42 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 393 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $317.61 | 45.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.49 | 19.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.86 | 12.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $87.27 | 12.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.90 | 5.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.32 | 3.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.97 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $706.42 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $163.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.49 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.12 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $87.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.13 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.40 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 393 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 218 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
218 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
393 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 984 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 968 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 812 | 141 |
| Furosemide | Furosemide | 811 | 162 |
| Montelukast Sodium | Montelukast Sodium | 743 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 713 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 702 | 133 |
| Meloxicam | Meloxicam | 671 | 129 |
| Omeprazole | Omeprazole | 667 | 136 |
| Gabapentin | Gabapentin | 649 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 569 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 107 |
| Metformin Hcl | Metformin Hcl | 483 | 95 |
| Citalopram Hbr | Citalopram Hydrobromide | 428 | 70 |
| Glimepiride | Glimepiride | 416 | 71 |
| Trazodone Hcl | Trazodone Hcl | 400 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 397 | 82 |
| Potassium Chloride | Potassium Chloride | 396 | 81 |
| Eliquis | Apixaban | 393 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 393 | 80 |
| Carvedilol | Carvedilol | 379 | 65 |
| Allopurinol | Allopurinol | 374 | 63 |
| Lisinopril | Lisinopril | 342 | 80 |
| Celecoxib | Celecoxib | 305 | 67 |
| Famotidine | Famotidine | 285 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 272 | 70 |
| Alendronate Sodium | Alendronate Sodium | 269 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 264 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 241 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 235 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 42 |
| Farxiga | Dapagliflozin Propanediol | 218 | 27 |
| Sertraline Hcl | Sertraline Hcl | 215 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 212 | 63 |
| Spironolactone | Spironolactone | 212 | 46 |
| Simvastatin | Simvastatin | 203 | 40 |
| Tramadol Hcl | Tramadol Hcl | 199 | 41 |
| Methylprednisolone | Methylprednisolone | 189 | 155 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 179 | 31 |
| Sucralfate | Sucralfate | 172 | 43 |
| Buspirone Hcl | Buspirone Hcl | 168 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 168 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 162 | 30 |
| Donepezil Hcl | Donepezil Hcl | 161 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 159 | 36 |
| Cefdinir | Cefdinir | 154 | 132 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 46 |
| Ozempic | Semaglutide | 149 | 28 |
| Levofloxacin | Levofloxacin | 140 | 109 |
| Alprazolam | Alprazolam | 132 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 40 |
| Pregabalin | Pregabalin | 132 | 28 |
| Chlorthalidone | Chlorthalidone | 130 | 26 |
| Memantine Hcl | Memantine Hcl | 121 | 23 |
| Lorazepam | Lorazepam | 113 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 109 | 24 |
| Meclizine Hcl | Meclizine Hcl | 108 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 102 | 52 |
| Entresto | Sacubitril/Valsartan | 98 | suppressed |
| Atenolol | Atenolol | 97 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 35 |
| Synthroid | Levothyroxine Sodium | 97 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 20 |
| Azithromycin | Azithromycin | 94 | 76 |
| Methocarbamol | Methocarbamol | 94 | 46 |
| Levetiracetam | Levetiracetam | 90 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 89 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | 13 |
| Baclofen | Baclofen | 82 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 80 | 14 |
| Clonidine Hcl | Clonidine Hcl | 79 | 13 |
| Ezetimibe | Ezetimibe | 78 | 16 |
| Myrbetriq | Mirabegron | 77 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 61 |
| Estradiol | Estradiol | 75 | 19 |
| Fluconazole | Fluconazole | 74 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 19 |
| Bupropion Xl | Bupropion Hcl | 72 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 15 |
| Clonazepam | Clonazepam | 64 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 13 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Bumetanide | Bumetanide | 60 | 14 |
| Temazepam | Temazepam | 60 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | suppressed |
| Cephalexin | Cephalexin | 56 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 12 |
| Prednisone | Prednisone | 54 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 13 |
| Dutasteride | Dutasteride | 52 | suppressed |
| Lovastatin | Lovastatin | 52 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | suppressed |
| Jardiance | Empagliflozin | 50 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 49 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 47 | 13 |
| Colestipol Hcl | Colestipol Hcl | 47 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 45 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 17 |
| Megestrol Acetate | Megestrol Acetate | 44 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 34 |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Colchicine | Colchicine | 41 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 12 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 36 | 36 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 27 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Torsemide | Torsemide | 26 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | 11 |
| Phenytoin | Phenytoin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Fetzima | Levomilnacipran Hcl | 11 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $706.42 · 31 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, Kerendia, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error